BioCentury
ARTICLE | Company News

Pfizer, Opko in $295M growth hormone deal

December 16, 2014 3:17 AM UTC

Opko Health Inc. (NYSE:OPK) gained $0.68 to $8.86 on Monday after granting Pfizer Inc. (NYSE:PFE) a worldwide license to commercialize the long-acting human growth hormone analog hGH-CTP.

Opko will receive $295 million up front and is eligible for $275 million in milestones, plus royalties on hGH-CTP and profit-sharing on both hGH-CTP and Pfizer's Genotropin somatropin hGH. ...